New trends for the medical treatment of endometriosis

Expert Opinion on Investigational Drugs

Volumn 21, Issue 7, 2012, Pages 905-919

  Rocha, Ana Luiza L ^a,b   Reis, Fernando M ^b   Petraglia, Felice ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Acupuncture; Antiangiogenic therapy; Antioxidant therapy; Endometriosis; Natural extracts; New treatment; Omega 3; Selective estrogen receptor modulator; Statins; Thiazolinedione; Vitamins

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA TOCOPHEROL; ANTIOXIDANT; AROMATASE INHIBITOR; ASCORBIC ACID; BAZEDOXIFENE; CABERGOLINE; CANNABINOID RECEPTOR AGONIST; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DOCOSAHEXAENOIC ACID; EPIGALLOCATECHIN GALLATE; GESTAGEN; GONADORELIN ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PROGESTERONE RECEPTOR MODULATOR; PYRIDOXINE; QUINAGOLIDE; RALOXIFENE; RETINOL; ROFECOXIB; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ANALGESIA; CYSTECTOMY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; DYSMENORRHEA; ENDOMETRIOSIS; FEMALE INFERTILITY; HORMONAL THERAPY; HUMAN; LAPAROSCOPIC SURGERY; PELVIS PAIN SYNDROME; QUALITY OF LIFE; REVIEW; SYSTEMATIC REVIEW;

ACUPUNCTURE THERAPY; DRUG THERAPY, COMBINATION; DRUGS, INVESTIGATIONAL; ENDOMETRIOSIS; FEMALE; HUMANS; PELVIC PAIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THERAPIES, INVESTIGATIONAL; TREATMENT OUTCOME;

EID: 84862282101     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2012.683783     Document Type: Review

References (170)

1. Giudice LC. Clinical practice. Endometriosis. N Engl J Med 2010;362(25):2389-98.
2. Bulun SE. Endometriosis. N Engl J Med 2009;360(3):268-79.
3. Fauconnier A, Chapron C. Endometriosis and pelvic pain: epidemiological evidence of the relationship and implications. Hum Reprod Update 2005;11:595-606 (Pubitemid 41631309)
4. Milingos S, Protopapas A, Drakakis P, et al. Laparoscopic management of patients with endometriosis and chronic pelvic pain. Ann NY Acad Sci 2003;997:269-73 (Pubitemid 38491082)
5. Kennedy S, Bergqvist A, Chapron C, et al. ESHRE guideline for the diagnosis and treatment of endometriosis. ESHRE Special Interest Group for Endometriosis and Endometrium Guideline Development Group. Hum Reprod 2005;20(10):2698-704
6. Berkley KJ, Rapkin AJ, Papka RE. The pains of endometriosis. Science 2005;308:1587-9; Endocrinology. 6th edition. Elsevier, New York; 2010. p. 2356-70 (Pubitemid 40807498)
7. Tokushige N, Markham R, Russell P, Fraser IS. Nerve fibres in peritoneal endometriosis. Hum Reprod 2006;21:3001-7 (Pubitemid 44567019)
8. Giudice LC, Kao LC. Endometriosis. Lancet 2004;364(9447):1789-99 (Pubitemid 39488065)
9. Beretta P, Franchi M, Ghezzi F, et al. Randomized clinical trial of two laparoscopic treatments of endometriomas: cystectomy versus drainage and coagulation. Fertil Steril 1998;70:1176-80 (Pubitemid 28546252)
10. Chapron C, Vercellini P, Barakat H, et al. Management of ovarian endometriomas. Hum Reprod Update 2002;8:6-7
11. Vercellini P, Chapron C, De Giorgi O, et al. Coagulation or excision of ovarian endometriomas? Am J Obstet Gynecol 2003;188:606-10 (Pubitemid 36332421)
12. Dousset B, Leconte M, Borghese B, et al. Complete surgery for low rectal endometriosis: long-term results of a 100-case prospective study. Ann Surg 2010;251(5):887-95
13. Moore J, Kennedy SH, Prentice A. Modern combined oral contraceptives for pain associated with endometriosis (Cochrane Review). In: The Cochrane Library. Issue 3. John Wiley & Sons Ltd; Chichester, UK: 2004
14. Prentice A, Deary AJ, Goldbeck WS, Farquhar C. Smith SK Gonadotrophin-releasing hormone analogues for pain associated with endometriosis. In: The Cochrane Library. Issue 3. John Wiley & Sons Ltd; Chichester, UK: 2004
15. Selak V, Farquhar C, Prentice A, Singla A. Danazol for pelvic pain associated with endometriosis (Cochrane Review). In: The Cochrane Library. Issue 3. John Wiley & Sons Ltd; Chichester, UK: 2004
16. Bahamondes L, Petta CA, Fernandes A, Monteiro I. Use of the levonorgestrel-releasing intrauterine system in women with endometriosis, chronic pelvic pain and dysmenorrhea. Contraception 2007;75(6 Suppl):S134-9 (Pubitemid 46770697)
17. Kauppila A, Ronnberg L. Naproxen sodium in dysmenorrhea secondary to endometriosis. Obstet Gynecol 1985;65:379-83 (Pubitemid 15134665)
18. Kauppila A, Puolakka J, Ylikorkala O. Prostaglandin biosynthesis inhibitors and endometriosis. Prostaglandins 1979;18:655-61 (Pubitemid 10204320)
19. Huirne JA, Lambalk CB. Gonadotropinreleasing-hormone-receptor antagonists. Lancet 2001;358(9295):1793-803
20. Struthers RS, Nicholls AJ, Grundy J, et al. Suppression of gonadotropins and estradiol in premenopausal women by oral administration of the nonpeptide gonadotropin-releasing hormone antagonist elagolix. J Clin Endocrinol Metab 2009;94(2):545-51.
21. Carr B, Chwalisz K, Jimenez R, et al. Elagolix, a novel oral GnRH antagonist, maintained reduction of endometriosis-associated pelvic pain during 24 weeks of treatments. Abstract Book. 11th World Congress on Endometriosis; 2011. p. 176-7
22. Al Kadri H, Hassan S, Al-Fozan HM, Hajeer A. Hormone therapy for endometriosis and surgical menopause. Cochrane Database Syst Rev 2009(1):CD005997.
23. Meresman GF, Bilotas M, Abello V, et al. Effects of aromatase inhibitors on proliferation and apoptosis in eutopic endometrial cell cultures from patients with endometriosis. Fertil Steril 2005;84:459-63 (Pubitemid 41125270)
24. Noble LS, Simpson ER, Johns A, Bulun SE. Aromatase expression in endometriosis. J Clin Endocrinol Metab 1996;81:174-9 (Pubitemid 26035021)
25. Kitawaki J, Noguchi T, Amatsu T, et al. Expression of aromatase cytochrome P450 protein and messenger ribonucleic acid in human endometriotic and adenomyotic tissues but not in normal endometrium. Biol Reprod 1997;57:514-19 (Pubitemid 27349909)
26. Kitawaki J, Kusuki I, Koshiba H, et al. Detection of aromatase cytochrome P-450 in endometrial biopsy specimens as a diagnostic test for endometriosis. Fertil Steril 1999;72:1100-6
27. Wolfler MM, Nagele F, Kolbus A, et al. A predictive model for endometriosis. Hum Reprod 2005;20:1702-8 (Pubitemid 40852269)
28. Velasco I, Rueda J, Acien P. Aromatase expression in endometriotic tissues and cell cultures of patients with endometriosis. Mol Hum Reprod 2006;12:377-81 (Pubitemid 43985608)
29. Hudelist G, Czerwenka K, Keckstein J, et al. Expression of aromatase and estrogen sulfotransferase in eutopic and ectopic endometrium: evidence for unbalanced estradiol production in endometriosis. Reprod Sci 2007;14:798-805 (Pubitemid 351903565)
30. Smuc T, Hevir N, Ribic-Pucelj M, et al. Disturbed estrogen and progesterone action in ovarian endometriosis. Mol Cell Endocrinol 2009;301:59-64
31. Ferrero S, Gillott DJ, Venturini PL, Remorgida V. Use of aromatase inhibitors to treat endometriosis-related pain symptoms: a systematic review. Reprod Biol Endocrinol 2011;9(1):89.
32. Ailawadi RK, Jobanputra S, Kataria M, et al. Treatment of endometriosis and chronic pelvic pain with letrozole and norethindrone acetate: a pilot study. Fertil Steril 2004;81:290-6 (Pubitemid 38223905)
33. Amsterdam LL, Gentry W, Jobanputra S, et al. Anastrazole and oral contraceptives: a novel treatment for endometriosis. Fertil Steril 2005;84:300-4 (Pubitemid 41125248)
34. Hefler LA, Grimm C, van Trotsenburg M, Nagele F. Role of the vaginally administered aromatase inhibitor anastrozole in women with rectovaginal endometriosis: a pilot study. Fertil Steril 2005;84:1033-6 (Pubitemid 41414604)
35. Remorgida V, Abbamonte LH, Ragni N, et al. Letrozole and desogestrel-only contraceptive pill for the treatment of stage IV endometriosis. Aust NZ J Obstet Gynaecol 2007;47:222-5 (Pubitemid 46909302)
36. Remorgida V, Abbamonte HL, Ragni N, et al. Letrozole and norethisterone acetate in rectovaginal endometriosis. Fertil Steril 2007;88:724-6 (Pubitemid 47368251)
37. Razzi S, Fava A, Sartini A, et al. Treatment of severe recurrent endometriosis with an aromatase inhibitor in a young ovariectomised woman. BJOG 2004;111(2):182-4 (Pubitemid 38186813)
38. Luisi S, Lazzeri L, Ciani V, Petraglia F. Endometriosis in Italy: from cost estimates to new medical treatment. Gynecol Endocrinol 2009;25(11):734-40
39. Ferrero S, Camerini G, Seracchioli R, et al. Letrozole combined with norethisterone acetate compared with norethisterone acetate alone in the treatment of pain symptoms caused by endometriosis. Hum Reprod 2009;24:3033-41.
40. Soysal S, Soysal ME, Ozer S, et al. The effects of post-surgical administration of goserelin plus anastrozole compared to goserelin alone in patients with severe endometriosis: a prospective randomized trial. Hum Reprod 2004;19:160-7 (Pubitemid 38072026)
41. Lossl K, Loft A, Freiesleben NLC, et al. Combined down-regulation by aromatase inhibitor and GnRH-agonist in IVF patients with endometriosis-a pilot study. Eur J Obstet Gynecol Reprod Biol 2009;144:48-53
42. Vercellini P, Somigliana E, Vigano P, et al. Endometriosis: current and future medical therapies. Best Pract Res Clin Obstet Gynaecol 2008;22(2):275-306 (Pubitemid 351305700)
43. Stygar D, Muravitskaya N, Eriksson B, et al. Effects of SERM (selective estrogen receptor modulator) treatment on growth and proliferation in the rat uterus. Reprod Biol Endocrinol 2003;1:40
44. Kulak J Jr, Fischer C, Komm B, Taylor HS. Treatment with bazedoxifene, a selective estrogen receptor modulator, causes regression of endometriosis in a mouse model. Endocrinology 2011; Epub ahead of print.
45. Saito T, Yaoshizawa M, Yamauchi Y, et al. Effects of the novel orally active antiestrogen TZE-5323 on experimental endometriosis. Arzneimittelforschung Drug Res 2003;53:507-14 (Pubitemid 36918536)
46. Yao Z, Shen X, Capodanno I, et al. Validation of rat endometriosis model by using raloxifene as a positive control for the evaluation of novel SERM compounds. J Invest Surg 2005;18:177-83 (Pubitemid 41200609)
47. Yavuz E, Oktem M, Esinler I, et al. Genistein causes regression of endometriotic implants in the rat model. Fertil Steril 2007;88(4 Suppl):1129-34 (Pubitemid 47513051)
48. Altintas D, Kokcu A, Kandemir B, et al. Comparison of the effects of raloxifene and anastrozole on experimental endometriosis. Eur J Obstet Gynecol Reprod Biol 2010;150(1):84-7
49. Stratton P, Sinaii N, Segars J, et al. Return of chronic pelvic pain from endometriosis after raloxifene treatment: a randomized controlled trial. Obstet Gynecol 2008;111(1):88-96
50. Anthony M, Williams JK, Dunn BK. What would be the properties of an ideal SERM? Ann NY Acad Sci 2001;949:261-78 (Pubitemid 34059989)
51. Chabbert-Buffet N, Meduri G, Bouchard P, Spitz IM. Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications. Hum Reprod Update 2005;11(3):293-307 (Pubitemid 40674206)
52. Spitz IM. Mifepristone: where do we come from and where are we going? Clinical development over a quarter of a century. Contraception 2010;82(5):442-52.
53. Huang HY. Medical treatment of endometriosis. Chang Gung Med J 2008;31(5):431-40
54. Chwalisz K, Garg R, Brenner RM, et al. Selective progesterone receptor modulators (SPRMs): a novel therapeutic concept in endometriosis. Ann NY Acad Sci 2002;955:373-88 (Pubitemid 34271095)
55. Wolf JP, Hsiu JG, Anderson TL, et al. Non-competitive antiestrogenic effect of RU 486 in blocking the estrogen-stimulated luteinizing hormone surge and the proliferative action of estradiol on endometrium in castrate monkeys. Fertil Steril 1989;52:1055-60 (Pubitemid 20011259)
56. Slayden OD, Zelinski-Wooten MB, Chwalisz K, et al. Chronic treatment of cyclic rhesus monkeys with low doses of the antiprogestin ZK 137 316: morphometric assessment of the uterus and oviduct. Hum Reprod 1998;13:269-77
57. Hodgen GD, van Uem JFHM, Chilik CF, et al. Non-competitive antioestrogenic activity of PAs in primate models. Hum Reprod 1994;9:77-82
58. Grow DR, Williams RF, Hsiu JG, Hodgen GD. Antiprogestin and/or gonadotropin-releasing hormone agonist for endometriosis treatment and bone maintenance: a 1-year primate study. J Clin Endocrinol Metab 1996;81:1933-9 (Pubitemid 26152488)
59. Madauss KP, Grygielko ET, Deng SJ, et al. A structural and in vitro characterization of asoprisnil: a selective progesterone receptor modulator. Mol Endocrinol 2007;21(5):1066-81 (Pubitemid 46984759)
60. Chwalisz K, Perez MC, Demanno D, et al. Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. Endocr Rev 2005;26(3):423-38 (Pubitemid 40686652)
61. Chwalisz K, Mattia-Goldberg K, Lee M, et al. Treatment of endometriosis with the novel selective progesterone receptor modulator (SPRM) asoprisnil. Fertil Steril 2004;82:S83-4
62. Carli C, Metz CN, Al-Abed Y, et al. Up-regulation of cyclooxygenase-2 expression and prostaglandin E2 production in human endometriotic cells by macrophage migration inhibitory factor: involvement of novel kinase signaling pathways. Endocrinology 2009;150(7):3128-37.
63. Chishima F, Hayakawa S, Sugita K, et al. Increased expression of cyclooxygenase-2 in local lesions of endometriosis patients. Am J Reprod Immunol 2002;48(1):50-6 (Pubitemid 34727375)
64. Cobellis L, Razzi S, De Simone S, et al. The treatment with a COX-2 specific inhibitor is effective in the management of pain related to endometriosis. Eur J Obstet Gynecol Reprod Biol 2004;116(1):100-2 (Pubitemid 39044502)
65. Ebert AD, Bartley J, David M. Aromatase inhibitors and cyclooxygenase-2 (COX-2) inhibitors in endometriosis: new questions-old answers? Eur J Obstet Gynecol Reprod Biol 2005;122(2):144-5
66. Machado DE, Berardo PT, Landgraf RG, et al. A selective cyclooxygenase-2 inhibitor suppresses the growth of endometriosis with an antiangiogenic effect in a rat model. Fertil Steril 2010;93(8):2674-9.
67. Olivares C, Ricci A, Bilotas M, et al. The inhibitory effect of celecoxib and rosiglitazone on experimental endometriosis. Fertil Steril 2011;96:428-33.
68. Hull ML, Prentice A, Wang DY, et al. Nimesulide, a COX-2 inhibitor, does not reduce lesion size or number in a nude mouse model of endometriosis. Hum Reprod 2005;20(2):350-8 (Pubitemid 40277601)
69. Novembri R, Luisi S, Carrarelli P, et al. Omega 3 fatty acids counteract IL-8 and prostaglandinE2 secretion induced by TNF-alpha in cultured endometrial stromal cells. J Endometriosis 2011;3(1):34-9.
70. Critchley HOD, Osei J, Henderson TA, et al. Hypoxia-inducible factor-1{alpha} expression in human endometrium and its regulation by prostaglandin E-Series Prostanoid Receptor2 (EP2). Endocrinology 2006;147:144-53
71. Howard FM. Endometriosis and mechanisms of pelvic pain. J Minim Invasive Gynecol 2009;16:540-50.
72. Chen DB, Yang ZM, Hilsenrath R, et al. Stimulation of prostaglandin (PG) F2 alpha and PGE2 release by tumour necrosis factor-alpha and interleukin-1 alpha in cultured human luteal phase endometrial cells. Hum Reprod 1995;10:2773-80
73. Covens AL, Christopher P, Casper RF. The effect of dietary supplementation with fish oil fatty acids on surgically induced endometriosis in the rabbit. Fertil Steril 1988;49:698-703
74. Netsu S, Konno R, Odagiri K, et al. Oral eicosapentaenoic acid supplementation as possible therapy for endometriosis. Fertil Steril 2008;90(4 Suppl):1496-502
75. Chegini N, Tang XM, Dou Q. The expression, activity and regulation of granulocyte macrophage-colony stimulating factor in human endometrial epithelial and stromal cells. Mol Hum Reprod 1999;5:459-66 (Pubitemid 29202202)
76. Nasu K, Fujisawa K, Arima K, et al. Expression and regulation of growth-regulated oncogene alpha in human endometrial stromal cells. Mol Hum Reprod 2001;7:741-6 (Pubitemid 32734297)
77. Boucher A, Kharfi A, Al-Akoum M, et al. Cycle-dependent expression of interleukin-1 receptor type II in the human endometrium. Biol Reprod 2001;65:890-8 (Pubitemid 32777377)
78. Rossi M, Sharkey AM, Vigano P, et al. Identification of genes regulated by interleukin-1b in human endometrial stromal cells. Reproduction 2005;130:721-9 (Pubitemid 41646057)
79. Harel Z, Biro FM, Kottenhahn RK, Rosenthal SL. Supplementation with omega-3 polyunsaturated fatty acids in the management of dysmenorrhea in adolescents. Am J Obstet Gynecol 1996;174:1335-8 (Pubitemid 26131157)
80. Gazvani MR, Smith L, Haggarty P, et al. High omega-3:omega-6 fatty acid ratios in culture medium reduce endometrial-cell survival in combined endometrial gland and stromal cell cultures from women with and without endometriosis. Fertil Steril 2001;76(4):717-22 (Pubitemid 32928397)
81. Lazzeri L, Luisi S, Sabbioni L, et al. Omega-3 fatty acids in the treatment of endometriosis related pain. Abstract Book. 11th World Congress on Endometriosis; 2011. p. 181
82. Franzoni F, Quinones-Galvan A, Regoli F, et al. A comparative study of the in vitro antioxidant activity of statins. Int J Cardiol 2003;90:317-21 (Pubitemid 37087893)
83. Foyouzi N, Berkkanoglu M, Arici A, et al. Effects of oxidants and antioxidants on proliferation of endometrial stromal cells. Fertil Steril 2004;82(Suppl 3):1019-22 (Pubitemid 39335910)
84. Piotrowski PC, Kwintkiewicz J, Rzepczynska IJ, et al. Statins inhibit growth of human endometrial stromal cells independently of cholesterol availability. Biol Reprod 2006;75:107-11 (Pubitemid 43946345)
85. Esfandiari N, Khazaei M, Ai J, et al. Effect of a statin on an in vitro model of endometriosis. Fertil Steril 2007;87:257-62 (Pubitemid 46188442)
86. Oktem M, Esinler I, Eroglu D, et al. High-dose atorvastatin causes regression of endometriotic implants: a rat model. Hum Reprod 2007;22:1474-80 (Pubitemid 47062821)
87. Bruner-Tran KL, Osteen KG, Duleba AJ. Simvastatin protects against the development of endometriosis in a nude mouse model. J Clin Endocrinol Metab 2009;94(7):2489-94.
88. Wilson WR, Evans J, Bell PR, Thompson MM. HMG-CoA reductase inhibitors (statins) decrease MMP-3 and MMP-9 concentrations in abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 2005;30:259-62 (Pubitemid 41086295)
89. Furman C, Copin C, Kandoussi M, et al. Rosuvastatin reduces MMP-7 secretion by human monocyte-derived macrophages: potential relevance to atherosclerotic plaque stability. Atherosclerosis 2004;174:93-8 (Pubitemid 38595445)
90. Cho SJ, Kim JS, Kim JM, et al. Simvastatin induces apoptosis in human colon cancer cells and in tumor xenografts, and attenuates colitis-associated colon cancer in mice. Int J Cancer 2008;123:951-7
91. Nap AW, Dunselman GA, de Goeij AF, et al. Inhibiting MMP activity prevents the development of endometriosis in the chicken chorioallantoic membrane model. Hum Reprod 2004;19:2180-7 (Pubitemid 39406673)
92. Sokalska A, Wong DH, Cress A, et al. Simvastatin induces apoptosis and alters cytoskeleton in endometrial stromal cells. J Clin Endocrinol Metab 2010;95(7):3453-9.
93. Wassmann S, Laufs U, Muller K, et al. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol 2002;22:300-5 (Pubitemid 34127043)
94. Wieser F, Cohen M, Gaeddert A, et al. Evolution of medical treatment for endometriosis: back to the roots? Hum Reprod Update 2007;13:487-99 (Pubitemid 47299854)
95. Wieser F, Burks-Wicks C, Vigne J, et al. Extracts from a traditional Chinese herbal remedy inhibit cell proliferation and induce apoptosis in human endometrial and endometriosis cells. In: Abstracts of the 61st Annual Meeting of the American Society for Reproductive Medicine, October 15-19, 2005, Montreal, Quebec, Canada. Fertil Steril 2005 84:S192; P113
96. Lian F, Liu HP, Wang YX, et al. Expressions of VEGF and Ki-67 in eutopic endometrium of patients with endometriosis and effect of Quyu Jiedu Recipe on VEGF expression. Chin J Integr Med 2007;13:109-14 (Pubitemid 47047570)
97. Wieser F, Yu J, Park J, et al. A botanical extract from channel flow inhibits cell proliferation, induces apoptosis, and suppresses CCL5 in human endometriotic stromal cells. Biol Reprod 2009;81(2):371-7.
98. Yang DX, Ma WG, Qu F, Ma BZ. Comparative study on the efficacy of yiweining and gestrinone for post-operational treatment of stage III endometriosis. Chin J Integr Med 2006;12(3):218-20 (Pubitemid 44534883)
99. Collins NH, Lessey EC, DuSell CD, et al. Characterization of antiestrogenic activity of the Chinese herb, Prunella vulgaris, using in vitro and in vivo (Mouse Xenograft) models. Biol Reprod 2000;80(2):375-83
100. Pezzuto JM. The phenomenon of resveratrol: redefining the virtues of promiscuity. Ann NY Acad Sci 2011;1215:123-30
101. Szekeres T, Saiko P, Fritzer-Szekeres M, et al. Chemopreventive effects of resveratrol and resveratrol derivatives. Ann NY Acad Sci 2011;1215:89-95.
102. Delmas D, Jannin B, Cherkaoui-Malki M, Latruffe N. Inhibitory effect of resveratrol on the of human and rat hepatic derived cell lines. Oncol Rep 2000;7:847-52
103. Delmas D, Passilly-Degrace P, Jannin B, et al. Resveratrol, a chemopreventive agent, disrupts the cell cycle control of human SW480 colorectal tumor cells. Int J Mol Med 2002;10:193-9
104. Delmas D, Rebe C, Lacour S, et al. Resveratrol-induced apoptosis is associated with Fas redistribution in the rafts and the formation of a death inducing signaling complex in colon cancer cells. J Biol Chem 2003;278:41482-90 (Pubitemid 37280977)
105. Delmas D, Rebe C, Micheau O, et al. Redistribution of CD95, DR4 and DR5 in rafts accounts for the synergistic toxicity of resveratrol and death receptors ligands in colon carcinoma cells. Oncogene 2004;23:8979-86 (Pubitemid 39657788)
106. Marel AC, Lizard G, Izard JC, et al. Effect of resveratrol derived molecules on the proliferation and the cell cycle progression of human tumoral cells. Mol Nut Food Res 2008;52:538-48
107. Lancon A, Delmas D, Osman H, et al. Human hepatic cell uptake of resveratrol: involvement of both passive diffusion and carrier-mediated process. Biochem Biophys Res Commun 2004;316:1132-7 (Pubitemid 38369070)
108. Lancon A, Hanet N, Jannin B, et al. Resveratrol in human hepatoma HepG2 cells: metabolism and inducibility of detoxifying enzymes. Drug Metab Dispos 2007;35:699-703 (Pubitemid 46641555)
109. Baarine M, Thandapilly SJ, Louis XL, et al. Pro-apoptotic versus anti-apoptotic properties of dietary resveratrol on tumoral and normal cardiac cells. Genes Nutr 2011;6(2):161-9.
110. Bruner-Tran KL, Osteen KG, Taylor HS, et al. Resveratrol inhibits development of experimental endometriosis in vivo and reduces endometrial stromal cell invasiveness in vitro. Biol Reprod 2011; 84(1):106-12.
111. Jackson LW, Schisterman EF, Dey-Rao R, et al. Oxidative stress and endometriosis. Hum Reprod 2005;20(7):2014-20 (Pubitemid 40932392)
112. Arumugam K, Dip YC. Endometriosis and infertility: the role of exogenous lipid peroxides in the peritoneal fluid. Fertil Steril 1995;63:198-9
113. Murphy AA, Palinski W, Rankin S, et al. Evidence for oxidatively modified lipid-protein complexes in endometrium and endometriosis. Fertil Steril 1998;69:1092-4 (Pubitemid 28274899)
114. Donnez J, Van Langendonckt A, Casanas-Roux F, et al. Current thinking on the pathogenesis of endometriosis. Gynecol Obstet Invest 2002;54(Suppl 1):52-8
115. Mier-Cabrera J, Jimenez-Zamudio L, Garcia-Latorre E, et al. Quantitative and qualitative peritoneal immune profiles, T-cell apoptosis and oxidative stress-associated characteristics in women with minimal and mild endometriosis. BJOG 2011;118(1):6-16.
116. Mier-Cabrera J, Aburto-Soto T, Burrola-Mendez S, et al. Women with endometriosis improved their peripheral antioxidant markers after the application of a high antioxidant diet. Reprod Biol Endocrinol 2009;7:54.
117. Mier-Cabrera J, Genera-Garcia M, De la Jara-Diaz J, et al. Effect of vitamins C and E supplementation on peripheral oxidative stress markers and pregnancy rate in women with endometriosis. Int J Gynaecol Obstet 2008;100(3):252-6. (Pubitemid 351258090)
118. Sesti F, Capozzolo T, Pietropolli A, et al. Recurrence rate of endometrioma after laparoscopic cystectomy: a comparative randomized trial between post-operative hormonal suppression treatment or dietary therapy vs. placebo. Eur J Obstet Gynecol Reprod Biol 2009;147(1):72-7.
119. Panina P, Mariani M, Camisa B, et al. The selective vitamin D receptor agonist elocalcitol reduces endometriotic lesion development in mice by inhibiting peritoneal inflammation. Abstract Book. 11th World Congress on Endometriosis; 2011. p. 188
120. Vigano P, Lattuada D, Mangioni S, et al. Cycling and early pregnant endometrium as a site of regulated expression of the vitamin D system. J Mol Endocrinol 2006;36(3):415-24 (Pubitemid 43904937)
121. Sharma I, Dhawan V, Saha SC, Dhaliwal LK. In vitro effects of peroxisome proliferator-activated receptor-gamma ligands on gene expression in lipopolysaccharide-induced endometrial and endometriotic stromal cells. Fertil Steril 2011;95(2):829-31.
122. Moravek MB, Ward EA, Lebovic DI. Thiazolidinediones as therapy for endometriosis: a case series. Gynecol Obstet Invest 2009;68(3):167-70.
123. Lebovic DI, Kir M, Casey CL. Peroxisome proliferator-activated receptor-gamma induces regression of endometrial explants in a rat model of endometriosis. Fertil Steril 2004;82(Suppl 3):1008-13 (Pubitemid 39341177)
124. Aytan H, Caliskan AC, Demirturk F, et al. Peroxisome proliferator- activated receptor-gamma agonist rosiglitazone reduces the size of experimental endometriosis in the rat model. Aust NZ J Obstet Gynaecol 2007;47:321-5 (Pubitemid 47079561)
125. Demirturk F, Aytan H, Caliskan AC, et al. Effect of peroxisome proliferator-activated receptor-gamma agonist rosiglitazone on the induction of endometriosis in an experimental rat model. J Soc Gynecol Investig 2006;13:58-62 (Pubitemid 43003568)
126. Herington JL, Crispens MA, Carvalho-Macedo AC, et al. Development and prevention of postsurgical adhesions in a chimeric mouse model of experimental endometriosis. Fertil Steril 2011;95:1295-301.
127. Lebovic DI, Mwenda JM, Chai DC, et al. Peroxisome proliferator-activated receptor-gamma receptor ligand partially prevents the development of endometrial explants in baboons: a prospective, randomized, placebo-controlled study. Endocrinology 2010;151:1846-52.
128. Lebovic DI, Mwenda JM, Chai DC, et al. PPAR-gamma receptor ligand induces regression of endometrial explants in baboons: a prospective, randomized, placebo-and drug-controlled study. Fertil Steril 2007;88:1108-19 (Pubitemid 47520613)
129. Mckinnon BD, Bersinger NA, Mueller MD. Regulation of IL-6 in cultured endometrial stromal cells by thiazolidiones. Abstract Book. 11th World Congress on Endometriosis; 2011. p. 182
130. Elden H, Ladfors L, Fagevik Olsen M, et al. Effects of acupuncture and stabilising exercises as adjunct to standard treatment in pregnant women with pelvic girdle pain. BMJ 2005;330:761
131. Highfield E, Laufer M, Schnyer R, et al. Adolescent endometriosis-related pelvic pain treated with acupuncture: two case reports. Altern Complement Med 2006;12:317-22
132. Lund I, Lundeberg T, Lonnberg L, Svennson E. Decrease of pregnant women's pelvic pain after acupuncture. Acta Obstet Gynecol 2006;85:12-19
133. Gerhard I, Postneek F. Auricular acupuncture in the treatment of female infertility. Gynecol Endocrinol 1992;6:171-81
134. Helms JM. Acupuncture for the management of primary dysmenorrhea. Obstet Gynecol 1987;69:51-6 (Pubitemid 17205380)
135. Pouresmail Z, Ibrahimzadeh R. Effects of acupressure and ibuprofen on the severity of primary dysmenorrhea. J Tradit Chin Med 2002;22:205-10 (Pubitemid 41246373)
136. French L. Dysmenorrhea. Am Fam Physician 2005;71(2):285-91
137. French L. Dysmenorrhea in adolescents: diagnosis and treatment. Paediatr Drugs 2008;10(1):1-7
138. Rubi-Klein K, Kucera-Sliutz E, Nissel H, et al. Is acupuncture in addition to conventional medicine effective as pain treatment for endometriosis? A randomised controlled cross-over trial. Eur J Obstet Gynecol Reprod Biol 2010;153(1):90-3.
139. McLaren J. Vascular endothelial growth factor and endometriotic angiogenesis. Hum Reprod Update 2000;6:45-55 (Pubitemid 30099342)
140. Cosin R, Gilabert-Estelles J, Ramon LA, et al. Vascular endothelial growth factor polymorphisms (-460C/T, +405G/C, and 936C/T) and endometriosis: their influence on vascular endothelial growth factor expression. Fertil Steril 2009;92:1214-20.
141. Tan XJ, Lang JH, Liu DY, et al. Expression of vascular endothelial growth factor and thrombospondin-1 mRNA in patients with endometriosis. Fertil Steril 2002;78:148-53
142. Ramon LA, Braza-Boils A, Gilabert-Estelles J, et al. MicroRNAs expression in endometriosis and their relation to angiogenic factors. Hum Reprod 2011;26(5):1082-90.
143. Machado DE, Abrao MS, Berardo PT, et al. Vascular density and distribution of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 (Flk-1) are significantly higher in patients with deeply infiltrating endometriosis affecting the rectum. Fertil Steril 2008;90(1):148-55 (Pubitemid 351885185)
144. Laschke MW, Menger MD. In vitro and in vivo approaches to study angiogenesis in the pathophysiology and therapy of endometriosis. Hum Reprod Update 2007;13:331-42 (Pubitemid 47062827)
145. Laschke MW, Elitzsch A, Vollmar B, et al. Combined inhibition of vascular endothelial growth factor (VEGF), fibroblast growth factor and platelet-derived growth factor, but not inhibition of VEGF alone, effectively suppresses angiogenesis and vessel maturation in endometriotic lesions. Hum Reprod 2006;21:262-8 (Pubitemid 41794320)
146. Imesch P, Samartzis EP, Schneider M, et al. Inhibition of transcription, expression, and secretion of the vascular epithelial growth factor in human epithelial endometriotic cells by romidepsin. Fertil Steril 2011;95(5):1579-83.
147. Laschke MW, Elitzsch A, Scheuer C, et al. Rapamycin induces regression of endometriotic lesions by inhibiting neovascularization and cell proliferation. Br J Pharmacol 2006;149(2):137-44 (Pubitemid 44360094)
148. Xu H, Lui WT, Chu CY, et al. Anti-angiogenic effects of green tea catechin on an experimental endometriosis mouse model. Hum Reprod 2009;24(3):608-18.
149. Laschke MW, Schwender C, Scheuer C, et al. Epigallocatechin-3-gallate inhibits estrogen-induced activation of endometrial cells in vitro and causes regression of endometriotic lesions in vivo. Hum Reprod 2008;23(10):2308-18
150. Ricci AG, Olivares CN, Bilotas MA, et al. Effect of vascular endothelial growth factor inhibition on endometrial implant development in a murine model of endometriosis. Reprod Sci 2011;18(7):614-22.
151. Becker CM, Beaudry P, Funakoshi T, et al. Circulating endothelial progenitor cells are up-regulated in a mouse model of endometriosis. Am J Pathol 2011;178(4):1782-91.
152. Van Langendonckt A, Donnez J, Defrere S, et al. Antiangiogenic and vascular-disrupting agents in endometriosis: pitfalls and promises. Mol Hum Reprod 2008;14(5):259-68 (Pubitemid 351804027)
153. Novella-Maestre E, Carda C, Noguera I, et al. Dopamine agonist administration causes a reduction in endometrial implants through modulation of angiogenesis in experimentally induced endometriosis. Hum Reprod 2009;24(5):1025-35.
154. Delgado-Rosas F, Gomez R, Ferrero H, et al. The effects of ergot and non-ergot-derived dopamine agonists in an experimental mouse model of endometriosis. Reproduction 2011;142(5):745-55.
155. Klein TW. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol 2005;5:400-11 (Pubitemid 40685989)
156. De Petrocellis L, Melck D, Palmisano A, et al. The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc Natl Acad Sci USA 1998;95:8375-80 (Pubitemid 28326120)
157. Melck D, De Petrocellis L, Orlando P, et al. Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology 2000;141:118-26 (Pubitemid 32260350)
158. Gomez del Pulgar T, Velasco G, Sanchez C, et al. De novo-synthesized ceramide is involved in cannabinoid-induced apoptosis. Biochem J 2002;363:183-8 (Pubitemid 34280625)
159. Bouaboula M, Poinot-Chazel C, Bourrie B, et al. Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. Biochem J 1995;312(Pt 2):637-41 (Pubitemid 26002235)
160. Rueda D, Galve-Roperh I, Haro A, Guzman M. The CB(1) cannabinoid receptor is coupled to the activation of c-Jun N-terminal kinase. Mol Pharmacol 2000;58:814-20
161. Akhmetshina A, Dees C, Busch N, et al. The cannabinoid receptor CB2 exerts antifibrotic effects in experimental dermal fibrosis. Arthritis Rheum 2009;60:1129-36
162. Defer N, Wan J, Souktani R, et al. The cannabinoid receptor type 2 promotes cardiac myocyte and fibroblast survival and protects against ischemia/reperfusioninduced cardiomyopathy. FASEB J 2009;23:2120-30
163. Garcia-Gonzalez E, Selvi E, Balistreri E, et al. Cannabinoids inhibit fibrogenesis in diffuse systemic sclerosis fibroblasts. Rheumatology 2009;48:1050-6
164. Julien B, Grenard P, Teixeira-Clerc F, et al. Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology 2005;128:742-55 (Pubitemid 40585376)
165. Michalski CW, Maier M, Erkan M, et al. Cannabinoids reduce markers of inflammation and fibrosis in pancreatic stellate cells. PLoS One 2008;3:e1701
166. Munoz-Luque J, Ros J, Fernandez-Varo G, et al. Regression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic rats. J Pharmacol Exp Ther 2008;324:475-83 (Pubitemid 351185849)
167. Teixeira-Clerc F, Julien B, Grenard P, et al. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat Med 2006;12:671-6 (Pubitemid 43865236)
168. Guindon J, Hohmann AG. Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. Br J Pharmacol 2008;153:319-34
169. Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006;58:389-462 (Pubitemid 44394908)
170. Tsou K, Lowitz KA, Hohmann AG, et al. Suppression of noxious stimulus-evoked expression of Fos protein-like immunoreactivity in rat spinal cord by a selective cannabinoid agonist. Neuroscience 1996;70:791-8 (Pubitemid 26009816)